Welcome to Visited Lingnan Modern Clinics In Surgery, Today is

Lingnan Modern Clinics In Surgery ›› 2022, Vol. 22 ›› Issue (04): 428-432.DOI: 10.3969/j.issn.1009-976X.2022.04.021

• Review • Previous Articles    

The role of protein glycosylation in the development of lung cancer

XU Sheng-shan, WANG Zhi-gang, LU Zhu-ming   

  1. Guangdong Medical University, Zhanjiang, Guangdong524023, China
  • Contact: LU Zhu-ming,mzl219@163.com

蛋白质糖基化在肺癌发生发展中的作用

徐圣善, 王志刚, 卢珠明*   

  1. 广东医科大学,广东湛江 524023
  • 通讯作者: *卢珠明,Email:mzl219@163.com

Abstract: Globally, lung cancer is the second-highest cancer incidence and remains the leading cause of cancer mortality worldwide. Early detection can greatly improve patient survival rates. However, the lack of reliable blood biomarkers remains a major factor in early diagnosis. Recent studies have shown that aberrant glycosylation plays an important role in tumor growth, invasion, and metastasis,and is closely related to the prognosis of lung cancer. The expression and regulation of proteins associated with lung cancer have a characteristic glycosylation pattern, and the detection of glycoproteins in tracheal secretions and blood is expected to be a biomarker for the early diagnosis of lung cancer. This article reviews the role of aberrant protein glycosylation in the progression of lung cancer.

Key words: lung cancer, glycosylation, targeted therapy, biomarker

摘要: 肺癌发病率居恶性肿瘤第二位,病死率居首位,早期发现可以大大提高患者的生存率。然而,缺乏可靠的血液生物标志物仍然是早期诊断的主要因素。最近的研究表明,异常的蛋白质糖基化在肿瘤生长、侵袭、转移等方面发挥重要作用,并与肺癌的预后密切相关,肺癌相关的蛋白质表达与调控具有特征性的糖基化模式,检测气管分泌物及血液中的糖蛋白有望成为早期诊断肺癌的生物标记物。本文就异常蛋白糖基化在肺癌进展中的作用进行综述。

关键词: 肺癌, 糖基化, 靶向治疗, 生物标志物

CLC Number: